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Vaccinia virus (VACV) encodes the soluble type I interferon (IFN) binding protein B18 that is secreted from infected cells and
also attaches to the cell surface, as an immunomodulatory strategy to inhibit the host IFN response. By using next generation
sequencing technologies, we performed a detailed RNA-seq study to dissect at the transcriptional level the modulation of the IFN
based host response byVACV and B18. Transcriptome profiling of L929 cells after incubationwith purified recombinant B18 protein
showed that attachment of B18 to the cell surface does not trigger cell signalling leading to transcriptional activation. Consistent
with its ability to bind type I IFN, B18 completely inhibited the IFN-mediated modulation of host gene expression. Addition of
UV-inactivated virus particles to cell cultures altered the expression of a set of 53 cellular genes, including genes involved in innate
immunity. Differential gene expression analyses of cells infected with replication competent VACV identified the activation of a
broad range of host genes involved in multiple cellular pathways. Interestingly, we did not detect an IFN-mediated response among
the transcriptional changes induced by VACV, even after the addition of IFN to cells infected with a mutant VACV lacking B18.
This is consistent with additional viral mechanisms acting at different levels to block IFN responses during VACV infection.
1. Introduction
Type I interferons (IFNs) constitute a family of related
cytokines (IFN-𝛼 subtypes, IFN-𝛽, and other IFN family
members) that bind a commonandheterodimeric cell surface
receptor (IFNAR) and play an important role in the first
line of defence against virus infections [1–3]. After initial
molecular recognition of the invading virus by host cell
pattern recognition receptors (PRRs), these IFNs are secreted
and bind cognate cellular receptors to exert their function
either locally or distally. This binding initiates the Janus
kinase (JAK)/signal transducers and activators of transcrip-
tion (STAT) signalling cascade to trigger the activation of
diverse host genes, depending on cell type, with potent
antiviral activity that contributes to the establishment of an
antiviral state in the adjacent healthy cells and the activation
of the apoptotic program to eliminate infected cells.Thus, the
main purpose of the IFN response is to limit virus replication
and infection spreading [4].
Vaccinia virus (VACV) is the most studied member of
the Poxviridae family of large DNA viruses with cytoplasmic
replication. VACV is the vaccine used to eradicate smallpox
more than 30 years ago and constitutes an excellent model to
analyze the evasion of the IFN based host response to viral
infection. Viruses have to neutralize the antiviral activity of
IFNs, and in this sense VACV and other poxviruses seem
to be unique encoding a plethora of genes to this effect
(reviewed in [2, 3, 5, 6]). Among others, VACV encodes
the A46 and A52 protein to inhibit toll-like receptor (TLR)
signalling that leads to IFN production [7] and VH1 to
dephosphorylate STAT1 and STAT2 [8, 9] but also diverse
proteins to specifically inhibit the antiviral activity of some
IFN-induced genes. This is the case of the E3 and K3
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proteins that employ two different mechanisms to counter-
act double-stranded RNA-dependent protein kinase (PKR)
effector functions [10, 11]. Additionally, E3 binds the product
of the IFN-stimulated gene 15 (ISG15) to prevent its antiviral
action [12]. But one the most efficient strategies employed
by poxviruses to avoid IFN effects is to encode IFN binding
proteins that are secreted from infected cells to prevent the
interaction of IFNs with their cellular receptors. In the case of
VACV strain Western Reserve (WR), the type I IFN binding
protein is encoded by theB18R gene (B19R in theCopenhagen
strain). A relevant role of this protein in VACV pathogenesis
was soon assigned, since the lack of B18R expression after
intranasal infection of mice resulted in an attenuated virus,
indicating that blocking the IFN host response is crucial for
the development of VACV infection [13].The B18 protein has
no amino acid sequence similarity to cellular IFN receptors
and, in contrast to the cellular counterparts, binds IFN𝛼/𝛽
from a broad range of host species [13]. The protein is
synthesized early after VACV infection, is secreted into the
medium, and is found as a soluble form or anchored to the
cell surface [14, 15]. This binding to the cell surface has been
shown to occur via interaction of the B18 amino terminus
with glycosaminoglycans (GAGs) [16] and allows B18 to
prevent the establishment of an IFN-induced antiviral state
in cells surrounding the infection site.
In the present study, by using RNA sequencing with the
Illumina technology (RNA-seq) and differential gene expres-
sion analyses, we have further analyzed the ability of B18 to
block the IFN based response in a mouse fibroblast cell line.
We also extend the study to VACV-infected cells to identify
changes in host gene expression profile induced by VACV or
a VACV mutant lacking the B18R gene (VACVΔB18), with
special emphasis on the inhibition of the type I IFN-induced
host cell response.
2. Materials and Methods
2.1. Cell Culture and Reagents. Mouse L929 cells were used to
obtain RNA samples for high-throughput sequencing, while
BSC-1 cells (African green monkey kidney origin) were used
to prepare virus stocks. Recombinant His-tagged VACV B18
protein was expressed in the baculovirus system and purified
as previously described [17]. Protein purity was checked on
Coomassie blue-stained SDS-PAGE and quantified by gel
densitometry. Murine recombinant IFN-𝛼 subtype A was
purchased from PBL Assay Science (>95% pure), diluted in
phosphate-buffered saline, and maintained at −70∘C until
use.
2.2. Viruses and Infections. Virulent VACV strain WR and
the correspondent VACV mutant lacking B18R expression
(VACVΔB18, [14]) were grown in BSC-1 cells and stocks of
semipurified virus were prepared by sedimentation through
a 36% sucrose cushion. L929 cells were infected with VACV
or VACVΔB18 with a multiplicity of infection of 5 plaque
forming units (pfu)/cell in order to ensure the infection
of all cells to obtain a representative RNA-seq profile of
each condition. After adsorption of virus for 1 h at 37∘C,
the virus-containing medium was removed, and cells were
washed twice with phosphate-buffered saline and replaced
with fresh culture medium supplemented with 2% fetal
bovine serum. Infected cells were then incubated at 37∘C
and harvested at 4 or 8 h postinfection (hpi) by scrapping.
Where indicated, IFN (50 units/ml) was added to the infected
cultures at 4 hpi and the incubation extended at 37∘C to 9 hpi.
Inactivation of viruseswas performed as previously described
[18], by incubation with 2𝜇g/ml psoralen (4-9-aminomethyl-
trioxsalen; Sigma) for 10min and then UV-irradiated for
10min with 2.25 J/cm2 in a Stratalinker 1800. Complete
inactivation (>108-fold reduction in pfu) was confirmed by
plaque assay in BSC-1 cells.
2.3. RNA Extraction and Illumina RNA-Seq Library Prepa-
ration. Immediately after harvesting the samples, total cel-
lular RNA was isolated from 1.2 × 106 L929 cells using
SV Total RNA Isolation System (Promega). RNA samples
were quantified on a spectrophotometer (NanoDrop ND-
1000; Thermo Scientific) and quality-analyzed in an Agi-
lent 2100 Bioanalyzer (Agilent Technologies, Santa Clara,
CA, US). All samples exhibited a RNA integrity number
(RIN) over 9. The sequencing libraries were generated with
TruSeq RNA Sample Prep Kit v2 Set A (Illumina). Briefly,
poly(A) containing mRNA molecules were purified in two
rounds using oligo(dT) attached magnetic beads from 1𝜇g
of total RNA. After chemical fragmentation, mRNA frag-
ments were reverse-transcribed and converted into double-
stranded cDNA molecules. Following end-repair and dA-
tailing, paired-end sequencing adaptors were ligated to the
ends of the cDNA fragments using TruSeq PE Cluster Kit v3-
cBot-HS (Illumina).
2.4. Deep Sequencing and Sequence Analysis. Libraries were
sequenced using TruSeq SBS Kit v3-HS (Illumina) on an
Illumina Hiseq 2000 machine at the Max Planck Insti-
tute for Molecular Genetics, Berlin. More than 108 100 nt
paired-end reads were obtained from each sample and
after quality assessment with package FastQC (http://www
.bioinformatics.babraham.ac.uk/projects/fastqc/), the fastq
files containing these reads were mapped to the mouse
genome (build GRCm38 from Mus musculus C57BL/6J
strain) together with the VACV WR genome (Genebank,
AY243312.1) using Tophat v2.0.4 with default parameters [19].
Only those reads aligned against mouse genomewere consid-
ered in a differential gene expression analysis with Cuffdiff
(Cufflinks v2.1.0 software [19]). Since biological duplicates
of samples from untreated cells were available, all compar-
isons were performed against this sample using the default
mode of Cuffdiff, which is the most suitable for our kind
of data. Pathway analysis of the significantly differentially
expressed genes detected was performed using Ingenuity
Pathway Analysis (IPA) software. Creation of proportional
Venndiagrams and gene expression heatmapswere generated
with the R “VennDiagram v1.6.9” and “Gplots” packages,
respectively. The raw RNA-seq data has been deposited at
the European Nucleotide Archive (ENA) under the project
number PRJEB15047.
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2.5. mRNA Expression by Real-Time-PCR (RT-PCR). To
evaluate the expression levels of selected genes by RT-PCR,
1 𝜇g of DNA-free total RNA isolated from L929 cells (three
biological replicates per condition) was used for first strand
cDNA synthesis with iScript cDNA Synthesis (BioRad) using
oligo(dT) and random primers. Quantitative polymerase
chain reaction (qPCR) analysis was performed using Fast
SYBR Green PCR Master Mix (Applied Biosystem) with
three technical replicates for each biological replicate,
according to the manufacturer’s recommendation in an ABI
7900 HT system (Applied Biosystem). Gene-specific qPCR
primers were designed using primer3Plus (http://www.bi-
oinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi/) and
described in Table S1 in Supplementary Material available
online at https://doi.org/10.1155/2017/5157626. Amplification
was real-time-monitored and allowed to proceed in the
exponential phase, until fluorescent signal reached a
significant value (Ct). The fold change was determined using
the 2−ΔΔC(t) method [20].
3. Results
3.1. The Type I IFN Cellular Response Is Inhibited in the
Presence of the VACV B18 Protein. To characterize the
inhibitory role of the VACV type I IFN binding protein
B18 on IFN signalling we analyzed the RNA-seq profile of
mouse L929 cells incubated with recombinant B18 before
and after IFN treatment. We first determined the effect of
type I IFN on global cellular gene expression and performed
high-throughput RNA sequencing on total RNA obtained
from cells mock-treated or treated with 50 units/ml of
IFN-𝛼 for 4 h. Under these conditions, we identified a set
of 46 significantly differentially expressed genes (SDEGs)
after IFN treatment when compared to mock-treated cells
(Table S2). Most of them (42 genes) were found to be
upregulated in response to IFN while only 4 genes were
downregulated. This set of IFN-stimulated genes (ISGs) con-
tained several genes with previously known direct antiviral
activity, such as APOL9, BST2 (Tetherin), DDX58 (RIG-1),
EIF2AK2 (PKR), IFITM3, ISG15, MX2, OAS-1, PARP12, or
TRIM. We also identified some ISGs involved in the positive
regulation of IFN production such as IRF9, STAT1, STAT2,
TRIM21, or TRIM30 and others encoding immunomodula-
tory molecules such as IL15, H2-Q1 (HLA-B), or UBC. We
considered this our high-confidence gene set and performed
a pathway enrichment analysis that mainly identified IFN
related canonical pathways as statistically significant enriched
(Figure 1(c)), indicating that L929 cells used in this study
exhibited an appropriate biological response to IFN.
However, when cells were incubated with 0.45 𝜇g/ml of
recombinant protein B18 2 h before IFN addition we could
not detect any significant change in cellular gene expression,
indicating that the IFN-induced cell response was efficiently
prevented by the addition of B18 (Figure 1). At the same time,
it was confirmed that this concentration of B18 effectively
protected against the antiviral effects of IFN (50U/ml) using
Vesicular stomatitis virus infection in HeLa cells (data not
shown).
B18 is secreted from VACV-infected cells and has been
previously shown to interact with GAGs at the surface of
uninfected neighbouring cells to exert its inhibitory function
[16]. This ability of B18 opens up the possibility of triggering
additional signalling cascades after binding to GAGs on the
cell surface. To test this possibility, cells were incubated
for 4 h with the same amount of recombinant B18 used
previously but in the absence of IFN. Importantly, under these
conditions, no significant changes in the gene expression
profile could be observed when compared to mock-treated
cells, indicating no activation of host gene expression is
triggered after the addition of B18 to cells (Figure 1).
To confirm these results, we selected three of the
genes upregulated after IFN addition from the RNA-seq
data (APOL9, IRF9, and OAS-1), together with other three
genes whose expression was unaffected (DBF4, GAPDH,
and MPRL2), and determined by RT-qPCR their expression
levels. As expected, we found significant increased gene
expression for APOL9, IRF9, and OAS-1 after IFN induction,
and, concordant with the results from RNA-seq, the addition
of B18 prior to IFN prevented this upregulation, keeping
their expression values similar to those found in untreated
cells (Figure 2). Moreover, DBF4, GAPDH, and MPRL2
expression determined by RT-qPCR remained unaffected
after IFN induction or B18 incubation, as seen in the RNA-
seq data (Figure 2).
3.2. VACV-Induced Changes on Cellular Gene Expression
Profile. Searching for the initial response to VACV infection,
we first explored by RNA-seq the transcriptomes of cells
infected with UV-inactivated VACV and compared it with
mock-treated cells. After alignment, only 0.17% of total reads
matched the viral genome (Table S3), mostly corresponding
to early VACV genes according to the temporal expression of
VACVORFs previously defined [21]. Under these conditions,
we could identify changes in the expression of a modest set of
53 cellular genes (Table S4). Among these, the upregulation
of some genes controlled by the NF-𝜅B complex such as
CCL5 (RANTES), H2-Q1 (HLA-B), the protein phosphatase
DUSP5 involved in negative regulation of MAP kinases,
the transcription factor FOSB, or SERPINE1 and also the
downregulation of the macrophage migration inhibitory
factor (MIF), CXCL1, ABCG1, SOD3, and negative regulator
of NF-𝜅B TRIB3 could represent the initial response to virus
infection in the absence of viral genome replication. However
the absence of type I IFN or IFN effectors should be noted.
By contrast, at 4 hpi with replication competent VACV,
around 30% of total reads matched the virus genome, and
a total of 2228 cellular genes were significantly differentially
expressed compared to uninfected cells, 887 upregulated and
1341 downregulated (Table 1). In order to gain a comprehen-
sive understanding of the transcriptomic changes induced by
VACV infection we evaluated pathway enrichment by these
SDEGs using Ingenuity Pathway Analysis (IPA) software.
At this time postinfection the analysis identified severe
alterations in cellular energy metabolism, since tricarboxylic
acid (TCA) cycle, mitochondrial dysfunction, glycolysis, or
oxidative phosphorylation represented the most significantly
4 Journal of Immunology Research
q < 0.05 = 0, not shown: 0)
q > 0.05 = 13718, not shown: 53)
q < 0.05 = 50, not shown: 2)
q > 0.05 = 13749, not shown: 88)
Sig (q < 0.05 = 0, not shown: 0)
Nosig (
Sig (
Nosig (
Sig (
Nosig (
q > 0.05 = 13645, not shown: 73)
B18 + IFN
−6
6
4
2
0
−2
−4
−8
−10
0 5 100 5 10
15
−10
− 5
−5
−5
0
5
10
10
−5
5
5
0
0
IFNB18
(a)
MX2
RTP4
DDX58
XAF1
IGTP
OASL1
OAS1B
ISG15
RHOD
PARP14
TRIM21
APOL9B
OAS1G
SLFN2
OAS1A
APOL9A
TRIM30A
SAMD9L
SLFN5
IRGM1
AY036118
PARP12
IRF9
RNF213
STAT2
TOR3A
H2-Q1
IL15
STAT1
IFI35
GM6548
EIF2AK2
KCNE4
LGALS3BP
BST2
EGR1
PNPLA6
TRIM25
IFITM3
MRGPRF
IER3
AKR1B3
WDR43
UBC
CD3EAP
RPS19-ps2
−4 0 4
IFN B18 +IFNB18
(b)
Canonical pathways
Interferon signaling
Activation of IRF by cytosolic pattern
recognition receptors
Role of pattern recognition receptors in
Recognition of bacteria and viruses
Role of RIG1-like receptors in antiviral innate
immunity
Communication between innate and adaptive
immune cells
7.87
6.48
4.15
2.33
1.73
Ratio
0.139
0.067
0.037
0.041
0.018
Molecules
OAS1, IFI35, STAT2, IRF9, STAT1
DDX58, STAT2, IRF9, STAT1, ISG15
OAS1, DDX58, Oas1b, EIF2AK2
DDX58, TRIM25
HLA-B, IL15
(1)
(2)
(3)
(4)
(5)
−log(p value)
(c)
Figure 1: Effect of B18 on type I IFN response. L929 cells were incubated with recombinant B18 protein (B18), with mouse IFN𝛼 (IFN), or
with recombinant B18 and then mouse IFN𝛼 (B18 + IFN), and analyzed by RNA-seq. (a) Corresponding𝑀/𝐴 plots representing expression
of all cellular genes. 𝑀 value (log 2 fold change) from each transcript between untreated and indicated sample cells is plotted against 𝐴
(overall average log expression level) of each untreated and indicated pair. Red dots indicate SDEGs when compared to untreated cells after
differential expression analysis. (b) Heatmap of SDEGs identified after IFN treatment.The heatmap displays the fold change expression (log 2)
in the indicated samples relative to results for untreated cells. The colour scale is shown at the bottom of the heatmap. (c) Enriched canonical
pathways after IPA analysis with SDEGs identified after IFN induction.
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Table 1: Alignment of Illumina reads and number of differentially expressed genes from infected cells with the indicated viruses.
PLWUV VACV VACV 4hpi VACV 9 hpi VACVΔB18 4 hpi VACVΔB18 9 hpi
Total reads aligneda 150.810.958 117.443.318 181.794.658 139.017.860 155.220.273
Viral readsb 260.091 (0.17%) 37.708.314 (32.1%) 144.727.059 (79.6%) 25.497.885 (18.4%) 90.326.955 (58.2%)
Cellular SDEGs Up Down Up Down Up Down Up Down Up Down
18 24 887 1341 2398 3753 660 1013 1238 2309
aAligned to either mouse or VACVWestern Reserve genomes.
bAligned exclusively to VACVWestern Reserve genome.
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Figure 2: Confirmation of RNA-seq data by RT-qPCR after IFN
induction. Gene expression for the indicated genes was assessed by
RT-qPCR from L929 cells after incubation with B18, 50 units/ml
IFN𝛼, or IFN togetherwith B18.𝛽-Actin genewas used as a reference
to normalize the data. Expression values are shown as fold change
compared to untreated cells (mean± SEMand significant differences
are displayed).
enriched pathways (Figure 3(a)). Some of these pathways
were predicted to be inhibited, indicating that infection was
suppressing levels of a broad variety of proteins involved in
energy metabolism early in infection. Signalling related to
cell proliferation and differentiation was also found to be
clearly affected during VACV infection, and examples were
ERK/MAPK or PI3K/AKT signalling pathways that were
modified. Differential expression of pathways specifically
associated with cell-cycle arrest, such as G1/S and G2/M
DNAdamage checkpoints, p53 signalling, or ATM signalling,
were also enriched following infection. Other significantly
enriched pathways, such as actin signalling, Rac signalling,
and integrin signalling, were related to cell migration and are
consistent with the previously described VACV-induced cell
motility during infection [22].
Most of these enriched pathways altered at 4 hpi were
also found to be modified later in infection (at 9 hpi, Fig-
ure 3(b)), showing higher 𝑝 values. However, at 9 hpi the
analysis detected a striking overrepresentation of cellular
genes involved in the modulation of protein translation.
We observed the downregulation of 165 genes encoding
ribosomal proteins and 45 encoding translation initiation
factors. As a consequence, the most significantly enriched
pathways identified at this time postinfection included EIF2
signalling, and regulation of EIF4 and p7056K and mTOR
signalling (Figure 3).
3.3. The Absence of B18 during VACV Infection Does Not
Markedly Alter the Cellular Gene Expression Profile. Previous
analysis revealed the absence of IFN related pathways among
enriched pathways altered after VACV infection, suggesting
the viral downmodulation of type I IFN based host responses.
Consistent with this, some of the ISGs with previously known
antiviral activity, such as APOL9A, APOL9B, OAS1a, or
OAS1g, exhibited lower expression levels in VACV-infected
cells at 4 hpi as compared to mock-infected cells. We next
evaluated the impact of B18 absence on cell host response
during infection by using a VACV deletion mutant lack-
ing expression (VACVΔB18). L929 cells were infected with
VACVΔB18 and the gene expression profile was determined
at 4 and 9 hpi and then compared to mock-infected cells. As
shown in Table 1, 20% and 60% of the total sequencing reads
corresponded to viral genes at 4 and 9 hpi, respectively. At 4 h
afterVACVΔB18 infection, a total of 1973 cellular SDEGswere
identified when compared to mock-infected cells and the
corresponding pathway enrichment analysis with these genes
revealed that although 188 SDEGs were found exclusively
differentially expressed during VACVΔB18 infection, most
of these changes in gene expression were similar to those
induced at the same times during wild type VACV infection,
and no additional pathways were found among the 200 most
significant enriched pathways (Figure 4).
3.4. Inhibition of the ISG Signature during VACV Infection
Is Not Exclusively Dependent on B18. We also analyzed the
IFN-mediated innate immune response after IFN treatment
of infected cells. To this end, the expression levels of the ISGs
previously identified after IFN treatment were determined
by RNA-seq under various conditions. L929 cells were either
(i) infected with wild type VACV and treated or not with
IFN at 5 hpi, once the IFN inhibitor B18 had been produced
and secreted; (ii) infected with VACVΔB18 and then treated
or not with IFN (in the absence of B18); or (iii) infected
with VACVΔB18 and supplemented with recombinant B18
before IFN addition. In all cases, total RNA was isolated
at 9 hpi (4 h after IFN addition) and processed as indicated
before. The results showed that addition of IFN to VACV-
infected cells did not result in a clear activation pattern of
the ISGs analyzed. We did not observe any difference in the
ISG profile in cells infected with wild type VACV in the
absence or presence of IFN, most likely due to the blocking
action of secreted B18 to prevent IFN engagement with IFN
cellular receptors. Surprisingly, even in cells infected with
VACVΔB18, not producing B18, the addition of IFN did not
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Figure 3: IPA analysis of differentially expressed host genes in VACV-infected cells. The list of SDEGs identified after VACV infection was
used in a pathway enrichment analysis with IPA software. The 40 most significant pathways identified at 4 hpi (a) and 9 hpi (b) after VACV
infection are shown. The 𝑥-axis represents the 𝑝 value, indicating the significance of enrichment for the corresponding gene set. The values
are plotted in a negative log10 scale.
result in an evident IFN based response, and the expression
levels of the ISGs analyzed were similar to those found in
VACVΔB18-infected cells in the presence of recombinant B18
protein and wild type VACV-infected cells (Figure 5).
In an independent assay, with additional RNA samples,
we could confirm these results by RT-qPCR in cells infected
with wild type VACV or VACVΔB18 in the same condi-
tions described above. We first verified the expression of
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Figure 4: Effect of B18 absence on host gene expression duringVACV infection. Venn diagrams showing the number of overlapped transcripts
corresponding to cellular genes differentially expressed between VACV- and VACVΔB18-infected cells at 4 hpi (a) and 9 hpi (b) are displayed.
the viral genes WR092 and WR127 in all infected cultures
and observed increasing expression values from 4 to 9 hpi,
independently of the addition of IFN. On the contrary, but
in concordance with results from the RNA-seq, the expres-
sion values of the ISGs determined by RT-qPCR (APOL9,
IRF9, and OAS1a) during wild type VACV or VACVΔB18
infections, and independently of the addition of IFN, were
similar in all cases to those detected in nontreated cells
(Figure 6). Finally, no significant modification of cellular
GAPDH expression levels, determined by RT-qPCR, was
observed at 4 h after infection while a slight decrease was
observed at 9 h during wild type VACV or VACVΔB18
infection in either the absence or presence of IFN.
4. Discussion
The secreted type I IFN binding protein B18 from VACV
represents a unique strategy employed by poxviruses to evade
the host IFN response. Its important contribution to the
virulence of VACV and ectromelia virus, a related mouse-
specific virus that also encodes a B18 orthologue, has been
demonstrated inmousemodels of infection [13, 23].This anti-
IFN activity has also been identified in the highly virulent
variola virus and monkeypox virus [17]. In this report we
have addressed the ability of the secreted type I IFN binding
protein to modulate the expression of host genes regulated
by IFN, using an RNA-seq approach to monitor the global
expression of host and viral genes.
First, we evaluated the impact of type I IFN on the
gene expression profile, required to induce an antiviral state
and protect cells from infection. In the case of L929 mouse
fibroblasts, we found the expression of 46 genes affected
by the addition of IFN-𝛼. Consistent with previous results
demonstrating the ability of B18 to block IFN effects [13–
16], the modulation of host gene expression by IFN could be
efficiently prevented by the action of B18.
Using the same RNA sequencing approach, the incuba-
tion of cells with purified B18 protein did not cause any
significant change in gene expression, suggesting that no
cell signalling is triggered by B18. This result is of particu-
lar relevance since, after secretion from infected cells, B18
interacts with GAGs at the surface of infected and adjacent
uninfected cells [14, 16], and GAGs have been shown to
regulatemultiple signalling pathways.This is the case of some
growth factors, such as fibroblast, hepatocyte, or vascular
endothelial growth factors [24–26], where the participation
of GAGs is essential for receptor-ligand engagement and the
resulting signalling. In contrast, our results clearly indicate
that the interaction of B18 with GAGs at the surface of L929
cells does not trigger any detectable cell signalling leading to
changes in host gene expression. Consistent with our results,
it has been reported that addition of purified recombinant B18
to primary mouse plasmacytoid cells does not induce type I
IFNproduction, whereas these cells were able to produce type
I IFN in response to TLR ligands [27].
In this report we have determined the cellular transcrip-
tome profile to investigate the changes in host expression
during VACV infection. The host reaction to VACV seems
to start immediately after infection, as deduced from the
set of genes differentially expressed 4 h after infection with
UV-inactivated VACV. Among these, we found some NF-
𝜅B regulated genes such as the proinflammatory chemokine
RANTES/CCL5 gene, genes involved in the regulation of
MAPK activity or the downregulation of antigen presentation
related gene H2Q1, among others. It was somehow surprising
that we did not detect more transcriptional activation in cells
incubated with UV-inactivated virus, which should be able
to attach and enter the cell. This may suggest that PRRs that
activate cells in response to VACV infection detect mainly
the viral genome that is being transcribed or replicated,
rather than the small amount of virus particles that enter
initially the cell (with viral proteins and DNA). Also, the
incoming virus particle contains VH1, a phosphatase known
to inhibit STAT1 and STAT2 activation, and may also prevent
IFN responses in the absence of virus replication, as it was
initially described [8]. Previous reports described the ability
of inactivated VACV WR and monkeypox virus to induce
the synthesis of IFN or IFN-inducible genes in plasmacytoid
dendritic cells and macrophages, respectively [27, 28], but we
could not detect the activation of these genes in L929 cells.
Two factors could contribute to explaining these differences:
the earlier timepoints analyzed compared with the previous
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Figure 5: ISGs expression during VACV infection. (a) Diagram showing the experimental conditions to obtain RNA samples from infected
cells. (b) Heatmap shows the expression levels of the ISGs previously identified relative to untreated cells, where indicated recombinant B18
protein (rB18) and/or mouse IFN𝛼 were/was added to cells at 2 and 5 hpi, respectively.
studies or the fact that the levels of IFN production are cell
type dependent. Plasmacytoid dendritic cells are considered
to be the professional type I IFN producing cells after viral
infections [29, 30] and secrete much more IFN-𝛼 than other
cell types.
By contrast, a drastic change in the host gene expression
profile occurred after 4 h of infection with replication com-
petent VACV, mainly affecting biological functions related
to metabolism, cell death and survival, cell development and
proliferation, and cell movement. Previous studies with HeLa
cells using microarrays or deep RNA sequencing showed a
general decrease in the cellularmRNAs uponVACV infection
[21, 31]. In our study, as previously reported by Yang et al.
[21], we found that the proportion of VACV mRNA was
approximately 30% of the total mRNA, andmore than 50% of
modified cellular genes were downregulated at 4 hpi, which is
indicative of the virus-induced degradation of cellularmRNA
that precedes host translation shutoff [32]. This effect was
even more pronounced at 9 hpi. Since the aim of our study
was to analyze themodulation of type I IFN responses by B18,
we selected the times postinfection that allowed the synthesis
and secretion into the supernatant of an effective amount of
the B18 protein, which is produced at early times of infection.
Under these conditions, we focused on type I IFN responses
upon VACV infection.
Our RNA-seq data from VACV-infected samples is in
concordance with previous reports showing that, unlike the
highly attenuated modified VACV Ankara (MVA) strain,
virulent VACV WR infection of mice or dendritic cell
cultures did not raise IFN-𝛼 responses. It is also known that
the lack of a functional B18R gene and other IFN inhibitors in
MVA allows the development of an IFN based host response
during infection [33]. However, our data indicated that the
infection with VACVΔB18, lacking expression of the secreted
type I IFN inhibitor, equally failed to raise an effective IFN
host response and VACVΔB18 infection proceeded similarly
to VACV infection in L929 cells. This result corroborates
the existence of additional viral mechanisms to inhibit the
induction of type I IFN responses, as previously indicated
by Waibler and cols during VACV infection of pDCs [27].
While B18 remains as the only identified secreted type I IFN
inhibitor, during the last years diverse VACV genes have been
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Figure 6: Confirmation of RNA-seq data by RT-qPCR during VACV infection. Gene expression for the indicated genes was assessed by RT-
qPCR from VACV- or VACVΔB18-infected L929 cells at 4 hpi and 9 hpi. IFN was added to infected cells at 5 hpi where indicated. Expression
levels ofWR092 andWR127 VACV genes were also determined tomonitor the progress of infection and relativized to VACV 4hpi expression
values. Mean from 3 biological replicates ± SEM and significant differences are displayed.
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shown to have a direct role in the inhibition of the IFN
production or the inhibition of the IFN signal transduction
that takes place after type I IFN binding to cellular IFNAR
[2]. Our results showed the lack of a functional IFN response
during VACV infection in the absence of B18, and even after
the addition of exogenous IFN-𝛼, indicating that the IFN
signalling downstream of IFNAR is impaired after VACV
infection. We speculate that the virion associated phos-
phatase VH1, which dephosphorylates STAT1 and STAT2 to
block downstream IFN-𝛼 signalling [8, 9], may contribute,
together with other VACV genes, to explaining this lack
of IFN responses during VACV infection in the absence of
B18 function. In the cellular experimental system used here
all cells were initially infected with VACV and hence the
inhibition of the IFN response by B18 cannot be appreciated.
The effect of B18 on virus replication in cell cultures treated
with IFN is evident under other circumstances, such as
when IFN is added a few hours after infection, as was
illustrated in a previous report [14]. Deletion of the type
I IFN binding protein in the VACV strain NYVAC has
been reported to trigger the activation of IRF3, IRF7, and
STAT1 and to increase the production of ISGs in human
monocytes, in a transcriptomic analysis using microarrays
[34]. The reasons for the different results reported in the
previous report may be due to a different response in human
monocytes or to the use of a highly attenuated VACV strain
lacking many immunomodulatory genes, such as C4L, N1L,
or N2L, which have been implicated in the modulation of
intracellular signalling events [35–37]. Also, the recombinant
viruses used in the NYVAC transcriptional studies have not
been controlled for the potential inadvertent selection of
mutations during the generation of the recombinant viruses,
through the construction of revertant viruses or sequencing
of the complete viral genomes, and thus the presence of
additional mutations in other genes that may influence the
reported results cannot be formally ruled out [38, 39].
The contribution of the secreted type I IFN binding pro-
tein to virus virulence and immune evasion becomes evident
in mouse models of VACV and ectromelia virus infection,
where mutant viruses show an attenuated phenotype that
is dramatic in the mousepox model [13, 23]. In the animal
host, the expression of a secreted IFN inhibitor is relevant
to efficiently block the protective effects of IFN, which is
produced in response to infection and is able to trigger IFN-
mediated antiviral activities in neighbouring cells and restrict
virus spread [23].
5. Conclusion
We have used RNA-seq to study by the modulation of the
type I IFN response by VACV and the secreted type I
IFN binding protein B18. This analysis identified cellular
pathways modulated during VACV infection or induced
by UV-inactivated virus particles. VACV B18 was a potent
inhibitor of the type I IFN response, consistent with its ability
to bind with high affinity IFN and to prevent its interaction
with cellular IFNAR. VACVΔB18 inhibits the IFN response
to an extent similar to that of wild type VACV, indicating
that VACV encodes numerous mechanisms to block the IFN
response and that the contribution of B18 to immune evasion
is more evident in infected mice than in tissue culture. We
also show that the interaction of B18 with cell surface GAGs
does not trigger a specific host response leading to changes in
host gene expression. The RNA-seq methodology allows the
evaluation of the global gene expression in infected cells and
the modulation of IFN responses by the VACV type I IFN
binding protein. Future RNA-seq studies in VACV-infected
micemay dissect better the ability of B18 tomodulate the type
I IFN-mediated response in different tissues.
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